Gerd Munzert serves as Chief Clinical Officer of NBE Therapeutics since June 2021. Gerd is a hematologist and medical oncologist with more than 20 years of experience in anticancer drug development.
Gerd has worked in different roles for Boehringer Ingelheim Oncology. He successfully led and steered clinical development of NCEs such as antimitotic kinases, EGFR tyrosine kinases and other targeted agents. In addition to his role at NBE Therapeutics, he maintains his affiliation with BI Oncology with responsibility for preclinical and early clinical compounds, translational programme's and external collaborations.
He attended medical school in Freiburg and Munich and did postdoctoral research at the University of Michigan, working on G-protein receptors in the lab of Prof. T. Yamada. In his further academic career, he focused on pathophysiology and treatment of leukemias and lymphomas at Ulm University where he maintains an affiliation as a lecturer.